Investigating genotype-to-phenotype correlation in CHARGE syndrome by deep phenotyping and multiparametric clustering.

CHARGE syndrome CHD7 clustering genotype-to-phenotype correlation non-sense mediated RNA decay

Journal

Clinical genetics
ISSN: 1399-0004
Titre abrégé: Clin Genet
Pays: Denmark
ID NLM: 0253664

Informations de publication

Date de publication:
10 2023
Historique:
revised: 17 04 2023
received: 10 02 2023
accepted: 12 05 2023
medline: 5 9 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: ppublish

Résumé

CHARGE syndrome, due to CHD7 pathogenic variations, is an autosomal dominant disorder characterized by a large spectrum of severity. Despite the great number of variations reported, no clear genotype-to-phenotype correlation has been reported. Unsupervised machine learning and clustering was undertaken using a retrospective cohort of 42 patients, after deep radiologic and clinical phenotyping, to establish genotype-phenotype correlation for CHD7-related CHARGE syndrome. It resulted in three clusters showing phenotypes of different severities. While no clear genotype-phenotype correlation appeared within the first two clusters, a single patient was outlying the cohort data (cluster 3) with the most atypical phenotype and the most distal frameshift variant in the gene. We added two other patients with similar distal pathogenic variants and observed a tendency toward mild and/or atypical phenotypes. We hypothesized that this finding could potentially be related to escaping nonsense mediated RNA decay, but found no evidence of such decay in vivo for any of the CHD7 pathogenic variation tested. This indicates that this milder phenotype may rather result from the production of a protein retaining all functional domains.

Identifiants

pubmed: 37243350
doi: 10.1111/cge.14363
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

466-471

Informations de copyright

© 2023 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.

Références

Pagon RA, Graham JM, Zonana J, Yong SL. Coloboma, congenital heart disease, and choanal atresia with multiple anomalies: CHARGE association. J Pediatr. 1981;99(2):223-227.
Vissers LELM, van Ravenswaaij CMA, Admiraal R, et al. Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet. 2004;36(9):955-957.
Bajpai R, Chen DA, Rada-Iglesias A, et al. CHD7 cooperates with PBAF to control multipotent neural crest formation. Nature. 2010;463(7283):958-962.
Bergman JEH, Janssen N, Hoefsloot LH, Jongmans MCJ, Hofstra RMW, van Ravenswaaij-Arts CMA. CHD7 mutations and CHARGE syndrome: the clinical implications of an expanding phenotype. J Med Genet. 2011;48(5):334-342.
Janssen N, Bergman JEH, Swertz MA, et al. Mutation update on the CHD7 gene involved in CHARGE syndrome. Hum Mutat. 2012;33(8):1149-1160.
Zentner GE, Layman WS, Martin DM, Scacheri PC. Molecular and phenotypic aspects of CHD7 mutation in CHARGE syndrome. Am J Med Genet A. 2010;152A(3):674-686.
Marcos S, Sarfati J, Leroy C, et al. The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical charge patients. J Clin Endocrinol Metab. 2014;99(10):E2138-E2143.
Narita A, Nagai M, Mizuno S, et al. Clustering by phenotype and genome-wide association study in autism. Transl Psychiatry. 2020;10(1):1-12.
Verloes A. Updated diagnostic criteria for CHARGE syndrome: a proposal. Am J Med Genet A. 2005;133A(3):306-308.
Hale CL, Niederriter AN, Green GE, Martin DM. Atypical phenotypes associated with pathogenic CHD7 variants and a proposal for broadening CHARGE syndrome clinical diagnostic criteria. Am J Med Genet A. 2016;170A(2):344-354.
Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine Learning in Python. J Mach Learn Res. 2011;12(Oct):2825-2830.
Sanlaville D, Etchevers HC, Gonzales M, et al. Phenotypic spectrum of CHARGE syndrome in fetuses with CHD7 truncating mutations correlates with expression during human development. J Med Genet. 2006;43(3):211-317.
Supek F, Lehner B, Lindeboom RGH. To NMD or not to NMD: nonsense-mediated mRNA decay in cancer and other genetic diseases. Trends Genet. 2021;37(7):657-668.
Sato H, Singer RH. Cellular variability of nonsense-mediated mRNA decay. Nat Commun. 2021;12(1):7203.
Toma KG, Rebbapragada I, Durand S, Lykke-Andersen J. Identification of elements in human long 3′ UTRs that inhibit nonsense-mediated decay. RNA. 2015;21(5):887-897.

Auteurs

Jérémy Dana (J)

Université Paris Cité, Institut Imagine, Inserm U1163, Paris, France.
Service de Radiologie Pédiatrique, AP-HP, Hôpital Necker Enfants Malades, Université Paris cite, Paris, France.
Department of Diagnostic Radiology, McGill University Health Centre, Montreal, Quebec, Canada.

Guillaume Dorval (G)

Université Paris Cité, Institut Imagine, Inserm U1163, Paris, France.
Service de Médecine Génomique des maladies rares, AP-HP.Centre, Hôpital Necker-Enfants Malades, Paris, France.

Christine Saint Martin (CS)

Department of Diagnostic Radiology, McGill University Health Centre, Montreal, Quebec, Canada.

Kahina Belhous (K)

Université Paris Cité, Institut Imagine, Inserm U1163, Paris, France.

Raphael Levy (R)

Université Paris Cité, Institut Imagine, Inserm U1163, Paris, France.

Sandrine Marlin (S)

Université Paris Cité, Institut Imagine, Inserm U1163, Paris, France.
Service de Médecine Génomique des maladies rares, AP-HP.Centre, Hôpital Necker-Enfants Malades, Paris, France.

Isabelle De Bie (I)

Division de génétique médicale, département de médecine spécialisée, centre universitaire de santé McGill, Montréal, Québec, Canada.

Manon Mautret-Godefroy (M)

Service de Médecine Génomique des maladies rares, AP-HP.Centre, Hôpital Necker-Enfants Malades, Paris, France.

Antonio Rausell (A)

Université Paris Cité, Institut Imagine, Inserm U1163, Paris, France.
Service de Médecine Génomique des maladies rares, AP-HP.Centre, Hôpital Necker-Enfants Malades, Paris, France.

Marlène Rio (M)

Université Paris Cité, Institut Imagine, Inserm U1163, Paris, France.
Service de Médecine Génomique des maladies rares, AP-HP.Centre, Hôpital Necker-Enfants Malades, Paris, France.

Elise Boucher-Brischoux (E)

Centre de génétique humaine, Université de Franche-Comté, Besançon, France.

Tania Attié-Bitach (T)

Université Paris Cité, Institut Imagine, Inserm U1163, Paris, France.
Service de Médecine Génomique des maladies rares, AP-HP.Centre, Hôpital Necker-Enfants Malades, Paris, France.

Nathalie Boddaert (N)

Université Paris Cité, Institut Imagine, Inserm U1163, Paris, France.
Service de Radiologie Pédiatrique, AP-HP, Hôpital Necker Enfants Malades, Université Paris cite, Paris, France.

Véronique Pingault (V)

Université Paris Cité, Institut Imagine, Inserm U1163, Paris, France.
Service de Médecine Génomique des maladies rares, AP-HP.Centre, Hôpital Necker-Enfants Malades, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH